49 results about "Trisaccharide" patented technology

The invention discloses a preparation method of chitosan oligosaccharide. The method comprises the following steps: adding chitin into concentrated hydrochloric acid, grinding until the chitin is dissolved into paste, washing with distilled water, and collecting to obtain a white colloidal substance, namely colloidal chitin; dissolving colloidal chitin in a phosphoric acid-citric acid buffer solution to obtain a mixed dissolved solution; adding a crude enzyme solution of composite chitinase into the mixed dissolving solution, placing the mixed dissolving solution in a shaking table for reaction, terminating the reaction in a boiling water bath, centrifuging, and carrying out activated carbon separation, low-temperature rotary evaporation concentration and freeze drying on supernate to obtain a chitosan oligosaccharide finished product. According to the method, chitinase crude enzyme liquid prepared from bacillus subtilis SH21 and chitinase crude enzyme liquid prepared from penicillium oxalicum K10 are used as compound enzymes, chitin is subjected to enzymolysis to prepare the chitosan oligosaccharide, the polymerization degree of the prepared chitosan oligosaccharide is 3-10, trisaccharide, tetrasaccharide, pentasaccharide and hexasaccharide are mainly used, and compared with single enzyme use, the compound enzymes are high in product yield and high in chitin degradation rate.

The invention relates to the technical field of sugar alcohol preparation, and discloses a preparation method of high-purity crystalline maltitol, which comprises the following steps: firstly, by taking corn starch milk as a raw material, preparing ultrahigh-content maltose syrup with the maltose content of more than or equal to 91%, the wheat triose content of less than or equal to 0.4% and the glucose content of less than or equal to 4% through an enzyme conversion method; carrying out hydrogenation reaction on the syrup by adopting a Raney nickel catalyst, and controlling the hydrogenation side reaction to be 2% or below, so as to obtain hydrogenated liquid with maltitol content of more than or equal to 88%; and then, a pigment separation procedure in a traditional process is omitted, and the hydrogenated liquid is directly subjected to decoloration, ion exchange, evaporation concentration, crystallization, centrifugation and drying treatment to finally prepare crystalline maltitol. According to the method, by screening a specific compound enzyme system and finely regulating the pH value and temperature control environment of a saccharification reaction system, the generation of maltose is effectively promoted, and side reactions such as excessive hydrolysis of glucose and reverse synthesis of trisaccharide are inhibited at the same time, so that the high-purity maltose syrup precursor is obtained.

The invention belongs to the technical field of biology, and particularly relates to Meyerozyma caribba XX2120, and the preservation number of the Meyerozyma caribba XX2120 is GDMCC No: 67777. The invention further relates to a preparation method of the Meyerozyma caribba XX2120. The strain is obtained by taking saccharomycetes X2120 as a starting strain, carrying out ARTP mutagenesis treatment and screening, has relatively strong acid resistance, relatively high salt stress resistance and certain alcohol resistance and aldehyde resistance, can effectively utilize monosaccharide, disaccharide and trisaccharide, has a wide utilization range on carbohydrate and has a relatively good utilization rate on inorganic nitrogen. Moreover, the strain can be used for producing mycoprotein through liquid fermentation by taking Luzhou-flavor distillers' grains as a raw material, and also can be used for performing solid fermentation on the Luzhou-flavor distillers' grains, so that the true protein content of the distillers' grains is increased, the nutritional value of the distillers' grains is improved, and the recycling of distillers' grain resources is effectively promoted.

A main object of the present invention is to provide a novel technique for activating T cell immune responses.SOLUTION: Solution to Problem The present inventors have found that the above problems can be solved by a compound represented by the general formula (I): wherein Sugar represents any monosaccharide, disaccharide, or trisaccharide; and R represents a hydrogen atom or an acyl group having 2 to 5 carbon atoms, or a salt thereof.SELECTED DRAWING: None

The invention discloses beta-N-acetyl hexosaminidase Fmhen (I436S), the amino acid sequence of the beta-N-acetyl hexosaminidase Fmhen (I436S) is shown as SEQ ID NO.5, and the beta-N-acetyl hexosaminidase Fmhen is applied to synthesis of lactose-N-trisaccharide II. The invention also discloses a beta-N-acetyl hexosaminidase Fmhex (W291A), wherein the amino acid sequence of the beta-N-acetyl hexosaminidase Fmhex is shown as SEQ ID NO. 6. The invention also discloses an application of the mutant in synthesis of lactose-N-trisaccharide II. According to the invention, beta-N-acetyl hexosaminidase Fmhex is subjected to mutation modification to obtain two mutants with higher transglycosylation activity, namely Fmhex (W291A) and Fmhex (I436S), the conversion rates of the prepared lactose-N-trisaccharide II are respectively 1.68 times and 1.88 times of those of the beta-N-acetyl hexosaminidase Fmhex, and the beta-N-acetyl hexosaminidase Fmhex has higher application potential. The research of the invention has important industrial production value and economic value.

This invention relates to a composition for improving alcoholic liver damage, belonging to the field of health product technology. This application provides the use of rhodioloside and lactose-N-trisaccharide in the prevention and / or inhibition of alcoholic liver disease. This application also provides a composition of human lactose oligosaccharides and rhodioloside. The compositions described in this application can prevent the occurrence of alcoholic liver disease or inhibit its further deterioration. This application provides a green, safe, and healthy composition, offering an ideal composition for protecting human health.

The invention discloses exo-type alginate lyase VsAly7C as well as a recombinant strain and application of the exo-type alginate lyase VsAly7C. The amino acid sequence of the exo-alginate lyase is as shown in SEQ ID No.4, and the nucleotide sequence for coding the amino acid sequence is as shown in SEQ ID No.1. The suitable reaction temperature of the exo-alginate lyase is 24-28 DEG C, and the exo-alginate lyase has high stability at 0-20 DEG C, so that the exo-alginate lyase can effectively degrade a substrate at low temperature, and belongs to cold-adapted alginate lyase. The exo-type alginate lyase has the capability of degrading alginate, polyG and polyM, the degradation mode is exo-type, and a final degradation product is unsaturated alginate trisaccharide and has NaCl dependence. The invention further constructs a recombinant vector and a recombinant thallus containing the exo-alginate lyase VsAly7C coding gene, and a good foundation can be provided for industrial application and production of unsaturated alginate oligosaccharides.

The invention relates to the technical field of gene engineering, and particularly discloses a chitinase truncated body, a recombinant expression vector thereof, and a construction method and application of engineering bacteria. The chitinase truncated body is Cq181NC, the amino acid sequence of the Cq181NC is as shown in SEQ ID NO: 1, and the nucleotide sequence for coding the chitinase is as shown in SEQ ID NO: 2. According to determination, the chitinase truncation provided by the invention has the advantages that the specific enzyme activity is obviously improved by 1.8 times compared with that of a wild type, the chitinase truncation is high in environmental change tolerance, and the thermal stability of the chitinase truncation is still 1.43 times that of the wild type (incubation is performed for 8 hours at 35 DEG C). More importantly, the spectrum of the enzymolysis product is changed: the wild type is mainly disaccharide and shows a typical excision enzyme mode; and the truncated Cq181NC generates a plurality of oligosaccharides including monosaccharide, disaccharide, trisaccharide and hexasaccharide, shows double catalytic characteristics of endonuclease and exonuclease, and has a better application prospect.

The invention provides a production method for increasing the yield of maltose, which comprises the following steps: proportioning, liquefying and saccharifying, controlling the concentration of starch milk through proportioning, reducing the concentration of syrup, improving the flowability of a system, obtaining a liquefied liquid with a low DE value in the liquefying process, and simultaneously adjusting the pH values of different reaction steps, so that the yield of maltose is increased. Finally, after saccharification is completed, the ultrahigh malt syrup which is low in content of glucose, maltose trisaccharide, maltose trisaccharide or more and high in maltose content is obtained, and the highest maltose content can reach 93%.

The invention relates to a group B streptococcus oligoglycoprotein conjugate as well as a preparation method and application thereof, and belongs to the technical field of group B streptococcus vaccine development. Inactivated group A streptococcus C5a peptidase ScpA193 is used as a carrier and is connected with group B streptococcus oligosaccharide antigens to prepare the group B streptococcus-resistant oligosaccharide protein conjugate, and the oligosaccharide antigens are oligosaccharide trisaccharide derivatives, oligosaccharide pentasaccharide derivatives or oligosaccharide octasaccharide derivatives of group B streptococcus cell wall surface polysaccharides. The oligosaccharide protein conjugate prepared by the invention can simultaneously induce two types of antibodies with different target spots to synergistically aim at group B streptococcus, and is a compound vaccine. The vaccine has better applicability, can more effectively inhibit group B streptococcus, and is not limited by the problem of bacterial drug resistance caused by use of a large amount of antibiotics.

The invention relates to a human milk oligosaccharide composition and application of the composition in preventing and / or inhibiting obesity and obesity-related diseases, and belongs to the technical field of human milk oligosaccharide application. The composition contains lactose-N-trisaccharide and other components, and the composition can prevent and / or inhibit obesity and prevent and / or regulate the fat content, cholesterol content, blood sugar and other indexes of a human body. The invention provides a green and healthy composition.

Disclosed is a novel lamellar structure regeneration agent for the stratum corneum. A lamellar structure regeneration agent according to the present invention contains hydrolyzed sericin as an active ingredient. The lamellar structure regeneration agent according to the present invention has the effect of regenerating a lamellar structure of intercellular lipids in the stratum corneum of the skin. The lamellar structure regeneration agent preferably further contains tocopheryl phosphate and / or a trisaccharide. The trisaccharide is preferably raffinose.

This invention discloses an antitumor natural drug composition based on Norway maple and its preparation method, relating to the field of biomedical technology. The compound is selected from at least one of the following structures: 3-O-[β-D-glucopyranosyl-(1→4)-[β-D-galactopyranosyl-(1→2)]]-β-D-glucopyranoside-21-O-acetyl-22-O-angeloyl yrutile alcohol, with the molecular formula C2. 55 H 86 O 23 This invention isolates a class of triterpenoid saponins with a rutinol skeleton from the bark of Norwegian maple, enriching the chemical composition library of maple species. The compounds contain unique oligosaccharide chains and diacyl substitution patterns at C-21 and C-22. One compound has a rare branched acyl group (3-hydroxy-4-methylhexanoyl) at C-21, while the other compound contains an arabinofuranose unit in its C-3 trisaccharide chain. These structural features are rare in natural products and demonstrate excellent structural novelty.

The invention discloses a method for increasing the yield of lactoyl-N-neotetraose based on genome integration and transporter screening, and belongs to the field of microbial genetic engineering. According to the invention, a lactoyl-N-trisaccharide II synthesis module and a lactoyl-N-neotetraose synthesis module are rapidly integrated to different sites of an escherichia coli genome in a multi-copy manner by virtue of a CRISPR (clustered regularly interspaced short palindromic repeats)-associated transsposases gene editing technology, so that the use of plasmids is reduced, and the metabolic burden of cells is reduced. And in a 3L bioreactor, the yield of the lactyl-N-neotetraose reaches 30.56 g / L. Through over-expression of the transporter, the transporter which is most obvious in improving the yield of the lactoyl-N-neotetraose is screened to be YbSET, the yield of the lactoyl-N-neotetraose reaches 54.12 g / L, and excellent industrial application prospects are shown.

We provide a technology that can activate NRF2. [Solution] An NRF2 activator comprising one or more chondroitin sulfate oligosaccharides selected from (a) to (c) below as an active ingredient: (a) a disaccharide having a chondroitin sulfate structure (a disaccharide of CS), (b) a trisaccharide having two N-acetyl-D-galactosamine residues and a chondroitin sulfate structure (a trisaccharide of CS having two GalNac residues), (c) a tetrasaccharide having a chondroitin sulfate structure (a tetrasaccharide of CS). According to the present invention, NRF2 can be activated. This is expected to promote homeostatic reactions in the body, such as antioxidant reactions, anti-inflammatory reactions, and detoxification reactions, and contribute to maintaining and improving health. It is also expected to contribute to the prevention and improvement of various unhealthy conditions and diseases caused by oxidative stress, inflammation, and toxic chemicals.

Disclosed are a chemical synthesis method for Vibrio cholerae serotype O100 O-antigen oligosaccharide, and a use, belonging to the technical field of chemistry. The present invention uses three monosaccharide building blocks and five kinds of carboxylic acid derivative, and under the effects of solvent, temperature and neighboring group participation, through orthogonal protection, selective assembly and amide coupling, five Vibrio cholerae serotype O100 O-antigen oligosaccharide fragments are synthesized. Using the synthesized oligosaccharide fragments, combined with NMR analysis and carbohydrate chip technology, the absolute configuration and immunological function of the 3,5-dihydroxyhexanoyl group in the O-antigen trisaccharide are clarified, providing a theoretical basis for further structure-activity research and minimal antigen epitope screening. The present invention has promising applications in the synthesis of Vibrio cholerae glycoconjugate vaccines and the development of new drugs.

To provide a plant milk exhibiting natural sweetness and a rich taste, maintaining fluidity even at a high solid content, being free from roughness or sedimentation, and offering high convenience.SOLUTION: A plant milk containing a saccharified grain liquid and satisfying the following (1) and (2). The plant milk preferably satisfies the following (3). The plant milk also preferably satisfies the following (4). (1) The total content of monosaccharides and disaccharides in a sugar composition is 25-75 mass%; (2) the content of trisaccharides or higher in the sugar composition is 25-75 mass%; (3) the proportion of monosaccharides in the total content of monosaccharides and disaccharides in the sugar composition is 50 mass% or more; and (4) the proportion of trisaccharides in trisaccharides or higher is 40 mass% or less.SELECTED DRAWING: None

A crystal of lacto-N-triaose, and belongs to the technical field of separation and purification. The technical solution is a crystalline form B of LNTII, which crystalline form has characteristic diffraction peaks at positions of 2θ values (2θ±0.2°) of diffraction angles of 3.98, 6.98, 8.30, 9.60, 18.68, 19.25, 19.89 and 20.72 in the powder X-ray diffraction pattern. Provided is a new crystalline form of lacto-N-triaose, thereby achieving the iteration of a technique for preparing LNTII and providing a reliable technique for industrial large-scale production.

The invention belongs to the technical field of molecular markers, and particularly relates to an InDel molecular marker related to the content of quercetin 3-O-glucosyl rhamnosyl glucoside (Q-Glu-Rha-Glu) of a tea tree and application of the InDel molecular marker. The invention discloses an InDel molecular marker related (closely linked) to the content of quercetin triglucoside in a tea tree, the molecular marker is pRUG-InDel, and the nucleotide sequence of the molecular marker is SEQ ID No: 1. The method is not limited by tea tree planting areas, tree ages, seasons, organ or tissue aging degrees and the like, the tea tree original variety and the Pu'er tea variety are rapidly and efficiently distinguished, and the Q-Glu-Rha-Glu content potentials of different tea tree germplasm resources are predicted.

The present invention relates to a cell-free enzyme-catalyzed process for producing glycoproteins of general formula (I) from a lipid-linked oligosaccharide and a peptide. Further, said process includes the construction of the lipid-linked oligosaccharide from a mannose trisaccharide containing core structure. Particularly, the lipid-linked oligosaccharide is a high mannose-, complex-, or hybrid-type N-glycan.

The invention relates to a novel application of HMOs, in particular to an application of HMO in preparation of an antioxidant and whitening composition, further relates to an antioxidant and whitening skin care composition, and belongs to the technical field of application of HMOs. According to the technical scheme, the invention relates to the application of lacto-N-triose II (lacto-N-triose II, LNT II) in the aspect of preparing the antioxidant and / or whitening composition. The invention further provides a composition with the antioxidant and / or whitening functions, the composition contains the lactose-N-trisaccharide, and preferably, the composition contains 0.8%-6% of the lactose-N-trisaccharide (LNT II). The invention provides an application of LNTII in the aspects of oxidation resistance and whitening, and provides a stable body lotion composition. According to the composition disclosed by the invention, due to the use of the LNTII, the use of other whitening compounds is reduced or avoided, and adverse reactions such as sensitization and the like can be avoided.

A composition for improving nicotinamide mononucleotide production, characterized by containing, as an active ingredient, at least one carbohydrate selected from the group consisting of monosaccharides (excluding glucose and xylose), disaccharides, trisaccharides, tetrasaccharides, pentasaccharides, sugar alcohols, and dietary fibers.

The invention relates to a preparation method and application of Tianshan Pleurotus tuber-regium trisaccharide. The method comprises the following steps: crushing Tianshan Pleurotus tuber-regium, extracting and degreasing with ethanol, extracting degreased powder with hot water, concentrating, precipitating with ethanol, and taking a supernatant part to obtain crude oligosaccharide of the Tianshan Pleurotus tuber-regium; decoloring and removing small molecules through AB-8 macroporous adsorption resin, separating through a DEAE anion exchange resin column, and separating and purifying through an activated carbon-diatomite column and a Bio P-2 chromatographic column to obtain the Pleurotus tuber-regium trisaccharide. According to the present invention, the molecular weight is determined to be 504 Da, the total sugar content is 986.68-993.43 mg / g, the yield of the Pleurotus tuber-regium trisaccharide is 0.08-0.12%, and with the Pleurotus tuber-regium oligosaccharide crude product as the raw material, the monosaccharide analysis result shows that the Pleurotus tuber-regium trisaccharide mainly comprises glucose and galactose. The Tianshan fungus and Pleurotus tuber-regium trisaccharide obtained by the method provided by the invention has the efficacy of improving respiratory system inflammation.

This present disclosure provides various diamine centered poly(amino acid)-saccharide-lipid conjugates. In various embodiments, the conjugates can safely be used as water solubility or bioavailability enhancers. In one aspect, the present disclosure provides a conjugate having the structural formula wherein B is a residue of a compound having three or four available binding positions, e.g., an alkylene diamine; S is a saccharide, for example, a residue of a mono-, di- or trisaccharide group, in which each saccharide unit is a sugar, a sugar alcohol, an amino sugar or a sugar acid; L is a lipophilic carrier residue selected from fatty acid residues (for example, residues of lauric acid, myristic acid, linoleic acid, palmitic acid, oleic acid and elaidic acid), steroid acid and sterol residues, and residues of retinoids carotenoids, tocopherols, and tocotrienols; Q is a residue of ethylene glycol, diethylene glycol, triethylene glycol, tetraethylene glycol, pentaethylene glycol or hexaethylene glycol; P is a residue of a polyaminoacid homopolymer; R2 is a terminal group selected from H, methyl, ethyl and maleimide; D is a secondary group that is as defined above for L or is a methyl-capped poly(ethylene glycol) residue; and d is 0, or d is 1.

We provide oligosaccharides with a novel structure. [Solution] The solution is β-D-fructopyranosyl-(2→6)-β-D-glucopyranosyl-(1→6)-D-glucose represented by formula (I). The β-D-fructopyranosyl-(2→6)-β-D-glucopyranosyl-(1→6)-D-glucose represented by formula (I) is useful as a novel oligosaccharide and can be used in food and beverage compositions. In addition, it can be used in pharmaceuticals and functional foods that exhibit effects such as improving the intestinal flora as a prebiotic, regulating bowel function, stimulating the immune system, and anti-caries effects.

The invention is in the technical field of synthetic biology and metabolic engineering. More particularly, the invention is in the technical field of culturing genetically engineered cells. The present invention describes: (i) a method for producing an oligosaccharide comprising milk-N-trisaccharide (LN3) or an oligosaccharide mixture comprising an oligosaccharide comprising LN3 by culturing a genetically modified cell comprising a transporter; and (ii) a genetically engineered cell for use in the method.

Provided is an oligosaccharide having a novel structure. SOLUTION: β-D-fructopyranosyl-(2→6)-β-D-glucopyranosyl-(1→6)-D-glucose is represented by formula (I). β-D-fructopyranosyl-(2→6)-β-D-glucopyranosyl-(1→6)-D-glucose represented by formula (I) is a useful novel oligosaccharide that can be used in food and beverage compositions, as well as in pharmaceuticals and functional foods that act as prebiotics to improve the intestinal flora, regulate the intestines, activate the immune system, and prevent dental caries.

To provide a novel compound exhibiting DPP-4 inhibitory activity and a method for producing a composition comprising the compound.SOLUTION: Provided is a compound represented by the following formula (1), obtained by a method including a step of extracting from fruits of Kochia scoparia, where X represents any one of a monosaccharide, a disaccharide, and a trisaccharide.SELECTED DRAWING: Figure 1

The present invention relates to an OMV vaccine that can prevent Helicobacter pylori infection and a preparation method thereof. The vaccine uses a conserved trisaccharide (Trio) in Helicobacter pylori lipopolysaccharide as a core antigen epitope, and its structure is α-DD-Hep-(1→3)-α-D-Fuc-(1→3)-β-D-GlcNAc-. The epitope is biosynthesized by recombinant Escherichia coli, and a non-reducing end of a core oligosaccharide on the Escherichia coli outer membrane vesicle (OMV) is used as a connection anchor. The oligosaccharide is catalyzed and synthesized by glycosyltransferases from Helicobacter pylori and Escherichia coli. Trio can be efficiently displayed on the surface of OMV using this oligosaccharide on the surface of bacteria. Animal experiments have shown that the vaccine has the ability to activate the body's immune response and protective efficacy, and can be developed as a vaccine to prevent Helicobacter pylori infection. It has important application value and significance for effectively preventing and treating diseases such as peptic ulcers, chronic inflammation, and even gastric cancer caused by Helicobacter pylori infection.